Latest Ratios: P/E Ratio -14.6x · EV/EBITDA N/A · ROE N/A. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $67M | $50M | $44M | $37M | — | — | — | — | — | — | — |
| Enterprise Value | $66M | $49M | $43M | $36M | — | — | — | — | — | — | — |
| P/E Ratio → | -14.58 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -2968.6% | -131.4% | -129.5% | -1595.3% | -1469.4% | — | — | -2.5% |
| ROA | -180.4% | -180.4% | -498.9% | -279.3% | -95.3% | -87.2% | -227.2% | -644.2% | — | — | -2.5% |
| ROIC | — | — | — | — | -1894.5% | — | — | -17587.1% | — | — | -3.0% |
| ROCE | — | — | — | -2927.3% | -149.6% | -156.8% | -1381.5% | -1362.5% | — | — | -3.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.02 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.92 | -1.28 | — | -1.88 | — | — | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 0.00 | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.02 | -8.02 | -14.95 | -136.39 | — | -2997.33 | -1298.12 | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.40 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.80 | 1.78 | — | — | 29.62 |
| Quick Ratio | 0.40 | 0.40 | 0.21 | 0.69 | 3.18 | 4.09 | 0.80 | 1.78 | — | — | 29.62 |
| Cash Ratio | 0.17 | 0.17 | 0.11 | 0.56 | 2.00 | 4.04 | 0.33 | 1.47 | — | — | 28.28 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | 0.02 | — | 384.88 | — | 1.74 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $39M | $29M | $22M | $15M | $10M | $9M | $8M | $6M | $6M | $6M |
Binary clinical trial dependency
As reported in recent financial filings, OKYO's TTM P/E ratio of -12.92 reflects a company in the pre-revenue clinical stage, where traditional valuation multiples are largely non-informative and fail to capture the speculative nature of the firm's pipeline-driven equity value relative to its peers.
The absence of positive earnings or revenue renders standard valuation multiples like P/E or EV/EBITDA ineffective for assessing the company's intrinsic value. Investors should instead focus on the probability-weighted net present value of the OK-101 program, as current market pricing appears to be driven by binary clinical outcomes rather than fundamental financial performance.
Based on the company's reported figures, the current ratio has deteriorated significantly from 4.09 in 2021Q4 to a precarious 0.58 in 2026Q2, indicating that OKYO's liquid assets are currently insufficient to cover its short-term liabilities without immediate external capital intervention.
This decline in liquidity highlights a heightened risk of a near-term solvency crisis, as the company lacks the operational cash flow to sustain its current burn rate. The reliance on external financing to meet short-term obligations suggests that the firm's financial flexibility is severely constrained, warranting close monitoring of potential dilutive events.
According to recent SEC filings, OKYO exhibits significant volatility in working capital management, with DPO figures reaching 773,862 in 2026Q2, which suggests that the company's cash position is highly sensitive to the timing of vendor payments and the accumulation of clinical trial-related accruals.
The extreme fluctuations in DPO indicate that the company may be stretching payables to preserve cash, a common but unsustainable tactic for pre-revenue entities. This lack of efficiency in managing working capital underscores the firm's dependence on external funding to bridge the gap between operational expenses and clinical milestones.
As disclosed in financial statements, the use of standard profitability metrics like ROE or Net Margin is fundamentally misapplied to OKYO, as these ratios obscure the reality that the company is currently in a capital-intensive, pre-revenue development phase rather than a mature operational state.
Investors should avoid relying on ROE or margin-based analysis, as these metrics are distorted by the absence of revenue and the impact of non-cash items like stock-based compensation. A more appropriate framework would involve evaluating the 'burn-to-milestone' ratio, which better captures the company's progress toward clinical data readouts relative to its remaining cash runway.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OKYO stock.
OKYO Pharma Limited's current P/E ratio is -14.6x. This places it at the 50th percentile of its historical range.
Based on historical data, OKYO Pharma Limited is trading at a P/E of -14.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.